ArticleScientific reports2016
Plasmid-mediated quinolone resistance determinants in quinolone-resistant Escherichia coli isolated from patients with bacteremia in a university hospital in Taiwan, 2001-2015.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Antibiotic resistance ofOpen veterinary journal · 2026Article
- Characterization of plasmid-mediated quinolone resistant genes among uropathogenic Escherichia coli isolates in Bushehr, south of Iran.BMC research notes · 2025Article
- Characteristics of quinolone resistance in Escherichia coli isolated from wildlife in Poland.Scientific reports · 2025Article
- Mechanisms of fluoroquinolone resistance among Escherichia coli isolates from urinary tract infections in Thailand.PloS one · 2025Article
- Analysis of molecular mechanisms of delafloxacin resistance in Escherichia coli.Scientific reports · 2024Article
- Article
- Prevalence and characterization of quinolone-resistantJournal of advanced veterinary and animal research · 2023Article
- Recent Advances in Strategies to Combat Bacterial Drug Resistance: Antimicrobial Materials and Drug Delivery Systems.Pharmaceutics · 2023Review
- Quinolone-resistant Escherichia coli at the interface between humans, poultry and their shared environment- a potential public health risk.One health outlook · 2023Article
- Tracking Antimicrobial ResistantMicroorganisms · 2022Article
- Characterization of Integrons and Quinolone Resistance in ClinicalInternational journal of microbiology · 2021Article
- Detection of OqxAB Efflux Pumps, a Multidrug-Resistant Agent in Bacterial Infection in Patients Referring to Teaching Hospitals in Ahvaz, Southwest of Iran.International journal of microbiology · 2021Article
- Genotypic antimicrobial resistance characterization of E. coli from dairy calves at high risk of respiratory disease administered enrofloxacin or tulathromycin.Scientific reports · 2020Article
- Extended-Spectrum Beta-Lactamase-ProducingFrontiers in public health · 2020Article
- Detection of Chromosomal and Plasmid-Mediated Quinolone Resistance AmongInfection and drug resistance · 2020Article
- Pandemic fluoroquinolone resistantProceedings of the National Academy of Sciences of the United States of America · 2019Article
- Plasmid-mediated fluoroquinolone resistance associated with extra-intestinalThe Indian journal of medical research · 2019Article
- The nature and epidemiology of OqxAB, a multidrug efflux pump.Antimicrobial resistance and infection control · 2019Review
- Prevalence of quinolone-resistant uropathogenicInfection and drug resistance · 2019Article
- Multiple mechanisms contributing to ciprofloxacin resistance among Gram negative bacteria causing infections to cancer patients.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to characterize fluoroquinolone (FQ)-resistant Escherichia coli isolates from bacteremia in Taiwan in 2001-2015. During the study period, 248 (21.2%) of 1171 isolates were identified as levofloxacin-resistant. The results of phylogenetic group analysis showed that 38.7% of the FQ-resistant isolates belonged to phylogenetic group B2, 23.4% to group B1, 22.6% to groupA, 14.9% to group D, and 0.4% belonged to group F. FQ-resistant isolates were highly susceptible to cefepime (91.5%), imipenem (96.0%), meropenem (98.8%), amikacin (98.0%), and fosfomycin (99.6%), as determined by the agar dilution method. β-lactamases, including blaTEM (66.1%), blaCMY-2 (16.5%), blaCTX-M (5.2%), blaDHA-1 (1.6%), and blaSHV-12 (1.6%), were found in FQ-resistant isolates. The results of PCR and direct sequencing showed that 37 isolates (14.9%) harbored plasmid-mediated quinolone resistance (PMQR) genes. qnrB2, qnrB4, qnrS1, coexistence of qnrB4 and qnrS1, oqxAB, and aac(6')-Ib-cr were found in 1, 4, 4, 1, 15, and 14 isolates, respectively. PMQR genes were successfully transfered for 11 (29.7%) of the 37 PMQR-harboring isolates by conjugation to E. coli C600. These findings indicate that qnr genes remained rare in E. coli but demonstrate the potential spread of oqxAB and aac(6')-Ib-c in Taiwan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.